| payload |
{"created_at":"2026-04-17T21:52:12.771 {"created_at":"2026-04-17T21:52:12.771882+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:6ebdbcafff884518","evidence_event_ids":["evt_d63b1b9d1558"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/what-309k-kiniksa-insider-sale-might-signal-amid-120-stock-surge","as_of":"2026-04-17T21:52:12.771882+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/17/what-this-usd309k-kiniksa-insider-sale-might-signal-amid-a-120-stock-surge/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/what-309k-kiniksa-insider-sale-might-signal-amid-120-stock-surge","article_chars":4868,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_77ac3e67401cecce","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/17/what-this-usd309k-kiniksa-insider-sale-might-signal-amid-a-120-stock-surge/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-17T23:48:57.330608+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsThe chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026.","fetched_title":"What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge | Nasdaq","final_url":"https://www.nasdaq.com/articles/what-309k-kiniksa-insider-sale-might-signal-amid-120-stock-surge","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/what-309k-kiniksa-insider-sale-might-signal-amid-120-stock-surge","source_event_id":"evt_d63b1b9d1558","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"880f96058440bd80","kind":"unusual_volume","published_at":"2026-04-17T21:16:54+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 9, 2026","May 24, 2025","April 17, 2026"],"entities":[{"asset_class":"equity","name":"Kiniksa Pharmaceuticals International, plc","relevance":"high","symbol":"KNSA","type":"company"},{"asset_class":"equity","name":"Michael R. Megna","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"Motley Fool","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"other","information_gaps":["Unusual volume delta metrics are not provided: baseline volume, current volume, and volume ratio vs average are missing.","The article does not explicitly confirm any unusual trading volume with market data; it only discusses the insider sale and general stock performance.","The catalyst hypothesis for the insider sale is limited to the article\u2019s framing (routine 10b5-1 plan); no alternative catalysts are evidenced in the text.","No explicit statement is provided about whether the insider sale is confirmed by additional news beyond the SEC Form 4 filing reference."],"key_facts":["Chief Accounting Officer Michael R. Megna sold 6,625 shares of Common Stock on April 9, 2026.","The sale proceeds were roughly $309,000, based on SEC Form 4 reported price of $46.69.","After the transaction, Megna reported still holding 27,418 Class A ordinary shares.","The article states the shares were disposed directly (no indirect or entity-attributed participation) and did not involve derivative securities.","The article states the sale was executed pursuant to a 10b5-1 trading plan adopted May 24, 2025.","The article notes Kiniksa\u2019s stock surged about 120% over the past year.","The article attributes the stock strength to operating momentum and cites 2025 ARCALYST revenue of $677.6 million and 2026 guidance of $900 million to $920 million.","The article characterizes the insider sale as routine/pre-planned rather than a shift in confidence."],"numeric_claims":[{"label":"insider_shares_sold","value":"6,625 shares"},{"label":"insider_sale_value","value":"~$309,000"},{"label":"reported_price_per_share","value":"$46.69"},{"label":"post_sale_holdings","value":"27,418 Class A ordinary shares"},{"label":"10b5-1_plan_adoption_date","value":"May 24, 2025"},{"label":"stock_surge_past_year","value":"~120%"}],"primary_claim":"On April 9, 2026, Kiniksa Pharmaceuticals International\u2019s Chief Accounting Officer Michael R. Megna sold 6,625 shares for roughly $309,000 under an SEC Form 4 transaction executed pursuant to a 10b5-1 trading plan.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported an insider sale by its Chief Accounting Officer on April 9, 2026: 6,625 shares sold for about $309,000. The article frames the trade as routine because it was executed under a 10b5-1 plan, despite the stock being up about 120% over the past year.","topics":["insider trading","SEC Form 4","10b5-1 trading plan","biopharmaceuticals","KNSA stock performance"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsThe chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026.","tickers":[],"title":"What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge","url":"https://www.fool.com/coverage/filings/2026/04/17/what-this-usd309k-kiniksa-insider-sale-might-signal-amid-a-120-stock-surge/"}}... |